151 related articles for article (PubMed ID: 7866380)
1. Artificial infections of Pneumocystis carinii in the SCID mouse and their use in the in vivo evaluation of antipneumocystis drugs.
Comley JC; Sterling AM
J Eukaryot Microbiol; 1994; 41(6):540-6. PubMed ID: 7866380
[TBL] [Abstract][Full Text] [Related]
2. The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy.
Kunz S; Junker U; Blaser J; Joos B; Meyer B; Zak O; O'Reilly T
J Antimicrob Chemother; 1995 Jul; 36(1):137-55. PubMed ID: 8537261
[TBL] [Abstract][Full Text] [Related]
3. Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats.
Schmatz DM; Powles MA; McFadden DC; Pittarelli L; Balkovec J; Hammond M; Zambias R; Liberator P; Anderson J
Antimicrob Agents Chemother; 1992 Sep; 36(9):1964-70. PubMed ID: 1416888
[TBL] [Abstract][Full Text] [Related]
4. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice.
Comley JC; Sterling AM
Antimicrob Agents Chemother; 1995 Apr; 39(4):806-11. PubMed ID: 7785975
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of Pneumocystis carinii Pneumonia in mice with benanomicin A (ME1451).
Yasuoka A; Oka S; Komuro K; Shimizu H; Kitada K; Nakamura Y; Shibahara S; Takeuchi T; Kondo S; Shimada K
Antimicrob Agents Chemother; 1995 Mar; 39(3):720-4. PubMed ID: 7793879
[TBL] [Abstract][Full Text] [Related]
6. Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs.
Walzer PD; Runck J; Steele P; White M; Linke MJ; Sidman CL
Antimicrob Agents Chemother; 1997 Feb; 41(2):251-8. PubMed ID: 9021175
[TBL] [Abstract][Full Text] [Related]
7. Atypical Pneumocystis carinii pneumonia: the potential hazards of empiric treatment.
Peters JW; Sattler FR
South Med J; 1983 Jun; 76(6):800-3. PubMed ID: 6602384
[TBL] [Abstract][Full Text] [Related]
8. Treatment of experimental Pneumocystis carinii infection by combination of clarithromycin and sulphamethoxazole.
Alder J; Mitten M; Shipkowitz N; Hernandez L; Hui YH; Marsh K; Clement J
J Antimicrob Chemother; 1994 Feb; 33(2):253-63. PubMed ID: 8182006
[TBL] [Abstract][Full Text] [Related]
9. Effect of sulfamethoxazole-trimethoprim and sulfadoxine-primethamine against fatal pneumocystosis in SCID mice.
Furuta T; Ito M; Kuramochi T; Hioki K; Nomura T
J Protozool; 1991; 38(6):221S-222S. PubMed ID: 1818179
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice.
Ito M; Nozu R; Kuramochi T; Eguchi N; Suzuki S; Hioki K; Itoh T; Ikeda F
Antimicrob Agents Chemother; 2000 Sep; 44(9):2259-62. PubMed ID: 10952565
[TBL] [Abstract][Full Text] [Related]
11. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone.
Medina I; Mills J; Leoung G; Hopewell PC; Lee B; Modin G; Benowitz N; Wofsy CB
N Engl J Med; 1990 Sep; 323(12):776-82. PubMed ID: 2392131
[TBL] [Abstract][Full Text] [Related]
12. Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.
Sheehan PM; Stokes DC; Yeh YY; Hughes WT
Am Rev Respir Dis; 1986 Sep; 134(3):526-31. PubMed ID: 3489425
[TBL] [Abstract][Full Text] [Related]
13. Improved rat model of Pneumocystis carinii pneumonia: induced laboratory infections in Pneumocystis-free animals.
Boylan CJ; Current WL
Infect Immun; 1992 Apr; 60(4):1589-97. PubMed ID: 1548080
[TBL] [Abstract][Full Text] [Related]
14. Resistance to trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. Implication of folinic acid.
Nunn PP; Allistone JC
Chest; 1984 Jul; 86(1):149-50. PubMed ID: 6610537
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.
Smego RA; Nagar S; Maloba B; Popara M
Arch Intern Med; 2001 Jun; 161(12):1529-33. PubMed ID: 11427101
[TBL] [Abstract][Full Text] [Related]
16. [An animal model of Pneumocystis carinii pneumonia and therapeutic efficacy of interferon-gamma in this model].
Nakamoto A; Kitsukawa K; Ishimine T; Inadome J; Kusano N; Fukuhara H; Saito A
Kansenshogaku Zasshi; 1993 Oct; 67(10):971-7. PubMed ID: 8254217
[TBL] [Abstract][Full Text] [Related]
17. Limited effect of trimethoprim-sulfamethoxazole prophylaxis on Pneumocystis carinii.
Hughes WT
Antimicrob Agents Chemother; 1979 Sep; 16(3):333-5. PubMed ID: 315754
[TBL] [Abstract][Full Text] [Related]
18. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
19. Failure of trimethoprim-sulfamethoxazole in the therapy of recurrent Pneumocystis carinii pneumonia.
Mitsuyasu RT; Corwin HL; Harris AA; Trenholme GM; Levi S; Karkusis PH
Am Rev Respir Dis; 1982 Jun; 125(6):762-5. PubMed ID: 6979960
[TBL] [Abstract][Full Text] [Related]
20. Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).
Bartlett MS; Fishman JA; Durkin MM; Queener SF; Smith JW
Exp Parasitol; 1990 Jan; 70(1):100-6. PubMed ID: 2295322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
